MedPath

Investigating the Safety and Performance of Two New 1-piece Ostomy Products Compared With SenSura 1-piece

Not Applicable
Completed
Conditions
Ileostomy - Stoma
Registration Number
NCT01957488
Lead Sponsor
Coloplast A/S
Brief Summary

The aim of the current investigation is to investigate the performance of two new 1-piece ostomy products

Detailed Description

The present investigation aims at testing the performance and safety of the two new 1-piece ostomy products

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
183
Inclusion Criteria
  1. Have given written informed consent and signed letter of authority (mandatory in DK)
  2. Be at least 18 years of age and have full legal capacity.
  3. Be able to handle the products themselves
  4. Have an ileostomy with a diameter between 10 and 40 mm.
  5. Have had their ostomy for at least three months.
  6. Have within the last month used a 1-piece flat product with open bag
  7. Currently using midi or maxi bags
  8. Willing to use minimum 1 product every second day, i.e. maximum 2 days wear time.
  9. Be suitable for participation in the investigation
  10. Must be able to use custom cut product
  11. Negative result of a pregnancy test for women of childbearing age (only DK)
Exclusion Criteria
  1. Currently receiving or have within the past 2 months received radio- and/or chemotherapy.
  2. Currently receiving or have within the past month received systemic steroid or local treatment in the peristomal area
  3. Are pregnant or breastfeeding
  4. Participating in other interventional clinical investigations or have previously participated in this investigation
  5. Has participated in the previous explorative Coloplast studies CP236 and CP237
  6. Are currently or during the study using ostomy belt
  7. Has a stoma below skin surface
  8. Currently suffering from peristomal skin problems (i.e.bleeding and/or broken skin)
  9. Has known hypersensitivity towards any of the test products

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Leakage14 +- 1 days

The fraction of baseplates with No leakage/seeping under the baseplate was measured. Leakage/seeping under the baseplate was assessed after each baseplate change.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (4)

Holtedam 3

🇩🇰

Humlebæk, Denmark

QPS Nederlands

🇳🇱

Groningen, Netherlands

Sykepleierklinikken

🇳🇴

Larvik, Norway

Synexus Limited

🇬🇧

Chorley, Lancashire, United Kingdom

Holtedam 3
🇩🇰Humlebæk, Denmark

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.